Lipocine Inc. (LPCN)

Market Cap	16.05M
Revenue (ttm)	11.20M
Net Income (ttm)	8,352
Shares Out	5.35M
EPS (ttm)	-0.00
PE Ratio	1,921.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,104
Open	3.010
Previous Close	3.010
Day's Range	3.010 - 3.010
52-Week Range	2.750 - 11.790
Beta	1.51
Analysts	Strong Buy
Price Target	10.00 (+233.32%)
Earnings Date	May 8, 2025

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which is in phase 3clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN
• Website: https://www.lipocine.com

Analyst Forecast

According to one analyst, the rating for LPCN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(233.32% upside)

Analyst Consensus: Strong Buy